Giorgio Ottaviani, PhD., DABT

 is VP of Preclinical Development at Ridgeline.

Giorgio is a drug development expert with proven successful scientific and global leadership track records.


Giorgio joined Ridgeline in 2018 from Roche where he served as Global Head of DMPK-PD Project Leaders and as Site Head of Non-Clinical Safety in Shanghai. Prior to Roche Giorgio worked at Novartis, Merck-Serono and in the biotech industry. Giorgio brings to Ridgeline a broad development expertise across therapeutic areas and modalities as well as proven ability to lead multi-disciplinary cross-cultural teams.


Giorgio earned a Ph.D in Pharmaceutical Chemistry from the University of Geneva (Switzerland) and is a certified toxicologist from the American Board of Toxicology (DABT).

Getting in touch


Ridgeline Therapeutics GmbH
A Versant Ventures Discovery Engine

Aeschenvorstadt 36

CH 4051 Basel


Offices  and Labs

Ridgeline Therapeutics GmbH
Hochbergerstrasse 60C
CH 4057 Basel

A Versant Ventures Discovery Engine.




Imprint  /  Privacy Policy  /  Terms of Use

© 2018 Ridgeline Therapeutics GmbH